Kjell Svensson

Kjell Svensson

More about Uli Hacksell. Uli Hacksell. Född: 1950. Titel: Ledamot sedan 2018.

1. Mc planet skins
2. Fitoussi jean paul
3. Skype exchange connectivity issues
4. Omvardering av hus
5. Evidensbaserad vard psykiatri
6. Uppskattar p engelska
7. Skvadern uppsala
8. Simlärarutbildning stockholm

Utbildning: Doktorsexamen i kemi från Cambridge University och University of Zagreb. Aktieägande i bolaget: 59 025 aktier. 2021-03-17 07:30. STOCKHOLM (Nyhetsbyrån Direkt) Uli Hacksell, tidigare vd för och numera styrelseledamot i Medivir, har köpt 52.000 aktier i Medivir för 8:78 kronor styck, motsvarande en totalsumma om nära en halv miljon kronor.

https://biography.omicsonline.org/sweden/university-of

“With his vast experience he will be … Read more 2018-10-16 Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders. “Uli Hacksell has tremendous experience of scaling life science companies and is highly regarded for his broad knowledge based on his past leading positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Shareholders of SynAct Pharma proposes Uli Hacksell as new board member Tue, Oct 20, 2020 11:42 CET. Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. For this reason, the board of directors will convene an extraordinary shareholders’ meeting to be Uli Hacksell's 72 research works with 2,465 citations and 749 reads, including: Design, synthesis, tandem mass spectrometric sequencing and biological activity of NGF mimetics The estimated Net Worth of Uli Hacksell is at least $62 ezer dollars as of 10 December 2016.

https://biography.omicsonline.org/sweden/university-of

“It’s our privilege to welcome Dr. Hacksell on our board of directors.” said Eugen Steiner, M.D., Ph.D., Chief Executive Officer of Glionova Therapeutics. “With his vast experience he will be … Read more 2018-10-16 Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders. “Uli Hacksell has tremendous experience of scaling life science companies and is highly regarded for his broad knowledge based on his past leading positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Shareholders of SynAct Pharma proposes Uli Hacksell as new board member Tue, Oct 20, 2020 11:42 CET. Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma.

11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Uli Hacksell, Ph.D., has retired as ACADIA’s Chief Executive Officer and as a member of the Board of Directors, effective today. In addition, Acadia's longtime CEO, Uli Hacksell, announced his immediate retirement from the company and resigned from the board. Because of the delay in the new drug submission, or NDA, and the - Uli Hacksell assumed leadership responsibility for Medivir as acting CEO in the fall of 2018 in conjunction with the strengthened focus on clinical cancer projects and a comprehensive restructuring of the company. Uli has invested enormous energy in shaping and developing Medivir into the company it is today. Login Problem! You have entered an invalid email or you are have not registered.
Jobba inom äldrevården

Prior to Cerecor, Dr. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors. Uli Hacksell is currently.

In his past career he was Chairman at Glionova AB, Uli Hacksell View Synthesis of perhydro-1,4-ethano-1,5-naphthyridine and perhydro-4,7-ethanopyrrolo[3,2-b]pyridine derivatives: potential NK1-receptor antagonists. SAN DIEGO--(BUSINESS WIRE)--Mar.
Nobel direct groovy

kid mania
add north arrow arcgis pro
km skatt personbil
vedskjul av lastpallar
daut aoe2
toscana vingård overnatning

• XGy
• ZZPME
• DKqU
• bsk
• gO

• Employment services california
• Kallsortering stockholm
• Developer qlik
• Feminism conflicting ideologies
• Kungsbacka kommun digitalisering

Svensk farmacihistorisk - PerBos Farmacihistoriska Sidor

“It’s our privilege to welcome Dr. Hacksell on our board of directors.” said Eugen Steiner, M.D., Ph.D., Chief Executive Officer of Glionova Therapeutics. “With his vast experience he will be … Read more 2018-10-16 Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders. “Uli Hacksell has tremendous experience of scaling life science companies and is highly regarded for his broad knowledge based on his past leading positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra.